Genetically controlled variation in ␣ 2 ␤ 1 expression by human blood platelets was previously described. Sixty-two haplotype sequences corresponding to the proximal 5 regulatory region (؊1096 to ؉1) of the ␣ 2 gene were compared, and a dimorphic sequence ؊52C>T was identified that is located precisely between 2 tandem Sp1/Sp3 binding elements previously shown to be absolutely required for transcriptional activity of this gene in epithelial cell lines and the erythroleukemic cell line K562. The gene frequency of ؊52T in a random Caucasian population is approximately 0.35, and the expression of ؊52T correlates directly with reduced densities of platelet ␣ 2 ␤ 1 . In mobility shift analyses, the ؊52T substitution attenuates complex formation with both Sp1 and Sp3. When transfected into the erythroleukemia cell line Dami, promoterluciferase constructs bearing the ؊52T sequence exhibit a 5-fold decrease in activity relative to the ؊52C construct. In transfected CHRF-288-11 megakaryocytic cells, the corresponding activity decreases by 10-fold. The ؊52T sequence appears to be in linkage disequilibrium with the previously defined allele A3 (807C; HPA-5b), known to be associated with diminished expression of platelet ␣ 2 ␤ 1 . In summary, a natural dimorphism has been identified within the proximal 5 regulatory region of the human integrin ␣ 2 gene that is responsible for decreased expression levels of the integrin ␣ 2 ␤ 1 on blood platelets through a mechanism that is probably mediated by the nuclear regulatory proteins Sp1 and Sp3. 
Introduction
The integrin ␣ 2 ␤ 1 is a receptor for both laminin and collagen on most cell types but binds exclusively to collagen when expressed on megakaryocytes and blood platelets. 1 A single copy of the ␣ 2 gene is present in the haploid genome, located on chromosome 5 (5q23-31). 2 We were the first to observe that there are marked differences in platelet ␣ 2 ␤ 1 density among healthy individuals 3, 4 and that these differences correlate with the inheritance of certain allelic combinations of the human ␣ 2 gene. 4 These findings have now been confirmed by others, [5] [6] [7] and the biologic and pathophysiologic implications of these differences are now the subject of increased scrutiny. Differences in platelet ␣ 2 ␤ 1 density correlate directly with the rate of platelet adhesion to collagen ex vivo. 4 The low-density alleles 2 and 3 (A2 and A3) are over-represented in symptomatic von Willebrand disease type 1 patients. 8 Thus, the inheritance of these alleles may predispose patients with von Willebrand disease to increased risk of bleeding. On the other hand, the expression of the high-density allele A1 is a risk factor for diabetic retinopathy 9 and for acute coronary disease (eg, myocardial infarction) or stroke in younger patients. 10, 11 The expression of ␣ 2 is known to be regulated at the transcriptional level in megakaryocytoid cells, [12] [13] [14] epithelial cells, 15 and fibroblasts. 16, 17 The first 961 base pairs (bp) of the 5Ј flanking region of K562 cell ␣ 2 DNA direct cell-type-specific suppressor and enhancer activity in cells of epithelial origin. 18 The sequence of this proximal 5Ј regulatory region reported by Zutter et al 12, 18 is most homologous to our allele A2, although a number of sequence differences have been found and are deposited in GenBank (accession no. AF062039). Five-prime to this region, an additional 4-kilobase (kb) sequence contains enhancer elements necessary for maximal transcription of the ␣ 2 gene in cells of megakaryocytic lineage. 12 In that distal segment, a 40-bp sequence is most critical for transcription enhancement in megakaryocytic cells. 13 In addition to this 5Ј regulatory region, partial sequences of the human ␣ 2 gene have been reported, 4 but the entire gene sequence remains to be determined.
In this study, we provide the first evidence that allelic differences in receptor density, initially observed on blood platelets, correlate with a dimorphism within the 5Ј regulatory region of the ␣ 2 gene. This dimorphism influences transcription by altering the affinity of the flanking sequences for the transcription factors Sp1 and Sp3. Furthermore, the sequence Ϫ52T, which attenuates Sp1/Sp3 binding and transcriptional activity, is in linkage disequilibrium with one of the alleles (A3) known to be associated with diminished expression of the integrin on platelets.
Patients, materials, and methods

Cell and tissue samples
Platelets and mononuclear cells were isolated from citrated whole blood, as described. 4 Personnel of the General Clinical Research Center (GCRC) at The Scripps Research Institute (TSRI) and Scripps Clinic, La Jolla, CA, recruited healthy blood donors and performed phlebotomies. In addition, DNA samples, derived from blood mononuclear cells of healthy subjects and hematologic patients, were provided through a collaborative study with Dr Augusto Federici (Milan, Italy). Dami cells were a generous gift from Dr David Wilcox (Medical College of Wisconsin, Milwaukee, WI). The megakaryocyte cell line CHRF-288-11 19 was a gift from Dr M. A. Lieberman (Cincinnati, OH).
Genotyping
Donor genotype was determined by BglII/AseI restriction fragment length polymorphism (RFLP) using blood mononuclear cell DNA (Figure 1 ). Exon sequence numbering is based on the incomplete human ␣ 2 complementary DNA sequence reported by Takada and Hemler. 20 Intron sequences flanking bp 807, 837, and 873 (introns F, G, and H) were derived in this laboratory (T.J.K.) and are available through GenBank (accession no. AF035968). A 1332-bp segment extending from the 3Ј region of intron G through most of exon 8 and encompassing the unique BglII and AseI sites (both located in intron G) was amplified from genomic DNA using the following primer pair: 5Ј primer (intron G; bp 2789-2812): 5Ј-GATTTAACTTTCCCGACTGCCTTC-3Ј; 3Ј primer (exon 8; bp 931-965): 5Ј-CTCTCTAGATTGTCATGGTTGCATTGATCAATCAC-3Ј.
The polymerase chain reaction (PCR) product (10 L) was incubated with 1 L BglII (New England Biolabs, Beverly, MA; NEB), 1 L AseI (NEB), and 2 L of the recommended reaction buffer (NEB no. 3) at 37°C for 2.5 hours. Reaction products were analyzed on a 2% agarose gel.
PCR amplification of proximal promoter sequences
Primers were designed to amplify a 437-bp genomic segment beginning at the proximal 5Ј regulatory region (nucleotide Ϫ244) and ending at nucleotide ϩ191. The sequence of the forward primer was 5Ј-CAG-GAAAGCCTGCCA-3Ј (A2ProF) and that of the reverse primer was 5Ј-TTGACTGAGCGCTACCACC-3Ј (A2ProR). From this PCR product, the sequence of the segment Ϫ146 to ϩ86 (which encompasses the Ϫ52 dimorphism) was obtained using the sequencing primers 5Ј-GGTTTGCA-GAGGATACCC-3Ј (A2ProR1), corresponding to nucleotides 69 to 86, and 5Ј-ACGAGCCGAGGTGCA-3Ј (A2ProF1), corresponding to nucleotides Ϫ146 to Ϫ131.
␣ 2 -luciferase fusion constructs
The proximal 5Ј regulatory region of the ␣ 2 gene corresponding to Ϫ244 through ϩ 40 was amplified by PCR using as template genomic DNA from a donor homozygous for Ϫ52C. The oligonucleotide primers were designed to incorporate KpnI (forward) and BglII (reverse) restriction sites, and the product was inserted into the polylinker site upstream of the luciferase (LUC) reporter gene in the plasmid pGL2-Enhancer (Promega, Madison, WI). The primer sequences were as follows (restriction sites underlined): A2PROFORKpnI: 5Ј-GAGGGTACCAGGAAAGCCTGCCA-3Ј; A2PROREV BglII: 5Ј-GAGAGAT CTAGAAGCTGTCCAGAGGGC-3Ј.
The desired plasmid p␣ 2 244-LUC was cloned in pGL2-Enhancer, and the insert sequence was confirmed in both directions using primers supplied by the manufacturer (GLprimer1 and GLprimer2; Promega). The plasmid p␣ 2 244⌬Ϫ52T-LUC was generated from p␣ 2 244-LUC as follows. The p␣ 2 244 insert was excised from pGL2-Enhancer using SmaI and HindIII restriction sites and cloned into the pALTER-1 vector (Promega). The Ϫ52T variant was then produced by mutagenesis using oligonucleotide Ϫ52T (5Ј-GGGGCGGGCTGGGGCGGGC-3Ј) according to the manufacturer's protocol. The mutated sequence was confirmed in both directions using SP6 and T7 primers (supplied by the manufacturer), and the insert was excised and cloned once again into pGL2-Enhancer. The sequence of the resultant plasmid p␣ 2 244⌬Ϫ52T-LUC was confirmed to be identical to p␣ 2 244-LUC except for the single base substitution Ϫ52T.
Quantitation of platelet ␣ 2 ␤ 1 by flow cytometry
With appropriate informed consent, blood samples were collected from healthy volunteers and processed in the GCRC of The Scripps Clinic. Six volumes of whole blood were mixed with 1 volume of acid-citrate dextrose-NIH formula A (ACD-A). An aliquot of whole blood was centrifuged over a cushion of Ficoll-Hypaque to isolate mononuclear cells that were preserved by freezing in dimethyl sulfoxide and served as a source of genomic DNA for genotyping. A second aliquot of whole blood was prepared for fluorescence-activated cell sorter (FACS) analysis, as described below. Within 4 hours of phlebotomy, 5 L whole blood was mixed with 40 L of 1% bovine serum albumin-Tyrode buffer (2 mM MgCl 2 , 137.5 mM NaCl, 12 mM NaHCO 3 , 2.6 mM KCl, pH7. 
Statistical analysis
Standard one-way ANOVA was employed to make comparisons of platelet ␣ 2 ␤ 1 density, as determined from flow cytometry binding measurements between subgroups with different ␣ 2 genotypes. If significant overall differences between the sample groups were found by ANOVA, we then used the Bonferroni multiple comparisons procedure to examine differences between pairs of sample groups.
Gel mobility shift analysis
Nuclear extracts were obtained from CHRF-288-11 or Dami cells by isolation of nuclei, as described. 21 An optimal number of cells (nominally, 0.5 ϫ 10 8 to 1 ϫ 10 8 ) were washed twice in PBS (centrifugation at 1800g for 10 minutes) and then lysed in 0.5 mL of 0.5% (vol/vol) Nonidet P-40 in 25 mM HEPES, 50 mM KCl, pH 7.9, containing 1 mM phenylmethylsulfonyl fluoride (PMSF), 100 M dithiothreitol (DTT), 10 g/mL leupeptin, and 20 g/mL aprotonin (lysis buffer). The nuclei were pelleted and rinsed once in lysis buffer without Nonidet P-40 (centrifugation at 10 000g for 1 minute). By vigorous micropipetting, nuclei were then physically disrupted in 25 mM HEPES, 500 mM KCl, pH 7.9, containing 10% (vol/vol) glycerol, 1 mM PMSF, 100 M DTT, 10 g/mL leupeptin, and 20 g/mL aprotonin (extraction buffer). When nuclei were sufficiently emulsified, the mixtures were centrifuged at 10 000g for 5 minutes, and the supernatants were collected. The concentration of nuclear proteins in the supernatants was determined by the method of Bradford. 22 Double-stranded DNA probes were end-labeled with ␣ 32 P-deoxycytidine triphosphate using Klenow DNA polymerase. 23 From 5 to 10 g nuclear protein was mixed with labeled DNA (5 ϫ 10 4 cpm) in 10 L of 25mM HEPES, 50 mM KCl, 0.5 mM EDTA, pH 7.9, containing 10% (vol/vol) glycerol, 0.5 mM PMSF, and 0.5 mM DTT (binding buffer) and incubated at ambient temperature for 1 hour. In reactions using competitor DNA, a molar excess (as indicated) of the unlabeled competitor DNA fragment was used. In antibody-based supershift or inhibitor experiments, 3 g anti-Sp1, anti-Sp3, anti-AP2, anti-nuclear factor-B (anti-NFB), or anti-Egr-1 (each from Santa Cruz Biotech, Santa Cruz, CA) was preincubated with the nuclear extract for 15 minutes at ambient temperature before addition of the ␣ 32 P-labeled probe. The reaction products were separated by polyacrylamide gel electrophoresis using 4% acrylamide/Bis (19:1) in 10.5 ϫ Tris-borate-EDTA buffer (TBE; Invitrogen, Carlsbad, CA). Protein complexes were visualized by autoradiography.
Transfection assays
The Dami and CHRF-288-11 cells were transfected by electroporation using a Cell-Porator (Life Technologies, Gibco, Gaithersburg, MD). Approximately 1 ϫ 10 7 cells were transfected in 500 L Iscove's modified medium containing 20 g plasmid DNA and 20 g pSV-␤-galactosidase DNA by electroporation at 300 V and 1180 F.
Results
The 5 regulatory region sequence
We have accumulated more than 20 kb of genomic sequence representing analogous regions of alleles A1, A2, and A3, including 5.5 kb of the 5Ј regulatory region, and these sequences can be obtained through GenBank (accession no. AF062039). Sixty-two haplotypes were compared in greater detail within the proximal regulatory region represented by residues Ϫ1069 to ϩ191. Although there is near identity (Ͼ 99.5%) between these haplotype sequences, one allelic substitution, Ϫ52CϾT, occurs with a gene frequency of 0.35.
To assess the relationship between nucleotide substitution Ϫ52CϾT and the A1, A2, and A3 alleles, we compared genotypes in a total of 110 individuals (Table 1) . A1, A2, and A3 were defined by BglII/AseI RFLP, as shown in Figure 1 and described in "Patients, materials, and methods." The Ϫ52CϾT dimorphism was defined by direct sequencing as described in "Patients, materials, and methods."
The most striking observation is that 7 of 7 donors who are homozygous for allele A3 are also homozygous for Ϫ52T. Moreover, each of 5 donors who are heterozygous for allele A3 (genotype 2/3 or 3/1) also expresses at least one Ϫ52T. This is evidence for linkage between these promoter sequences and those downstream sequence substitutions that define allele A3, such as 807C and 1648A (HPA-5b). 24, 25 Additional donors need to be genotyped to determine whether there is any further linkage disequilibrium between the already established alleles (A1 or A2) and these promoter dimorphisms.
This naturally occurring dimorphism is located precisely in the middle of tandem Sp1/Sp3 binding elements of the core promoter, previously defined by Zutter 14 and Ye 26 ( Table 2 ). The published core promoter sequence contains 2 Sp1/Sp3 binding elements, labeled (from right to left) A and B, separated by a single nucleotide, the CϽT substitution at position Ϫ52.
Donor differences in platelet ␣
The surface content of platelet ␣ 2 ␤ 1 in whole blood was measured by flow cytometry, employing either of 2 murine monoclonal anti-␣ 2 ␤ 1 antibodies, 8C12 or 12F1. Identical findings were made with both antibodies, and the results obtained using 8C12 are depicted in Figure 2 . 
Mutant AB is the negative-binding oligonucleotide. Ϫ indicates sequence identity.
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There is clearly an inverse relationship between the number of inherited substitutions within the promoter regions and the platelet density of ␣ 2 ␤ 1 , and this relationship is statistically significant. In particular, the platelet integrin level in donors who are homozygous for Ϫ52T is consistently much lower than that of donors who do not express this substitution (ie, who are homozygous for Ϫ52C).
The influence of the C>T substitution at position ؊52 on the binding of nuclear proteins
Using gel mobility shift analysis, we found that nuclear proteins from Dami, K562, and CHRF-288-11 cells bind to a 28-bp core promoter fragment (bp Ϫ65 to Ϫ38) that contains the 2 tandem Sp1/Sp3 binding elements, designated A and B in Table 2 . The CϾT base substitution at Ϫ52 has a significant effect on the binding of both Sp1 and Sp3 to the flanking sequences. The oligonucleotide probes employed for these studies are listed in Table 2 .
Nuclear proteins from the Dami cell line form specific complexes with either the Ϫ52C or the Ϫ52T probes (Figure 3) , and essentially identical results are obtained with either CHRF-288-11 or K562 cell line (not shown).
In a representative gel mobility shift assay, using a nuclear extract from Dami cells (Figure 3 ), 3 major complexes are formed in the presence of Ϫ52C (lane 1) and are designated I through III, from the slowest to fastest mobility. Based on differential precipitation with polyclonal anti-Sp1 or anti-Sp3, these complexes are formed by the binding of (I) Sp3 only, (II) Sp1 only, and (III) Sp3 only. The experimental basis for these identifications is summarized below. Complexes I and III are each supershifted in the presence of anti-Sp3 antibody (lanes 7, 8) . Conversely, complex II is selectively supershifted in the presence of anti-Sp1 antibody (lanes 5, 6, 14, 15) . None of the 3 complexes are formed in the presence of the control probes A (lane 4) or mutant AB (not shown), and none is supershifted by antibodies specific for AP2 (lanes 10, 11), NFB (lanes 12, 13), or Egr-1 (not shown).
In the presence of Ϫ52T, complex formation with either Sp3 (lanes 2, 6) or Sp1 (lanes 2, 8) is markedly diminished. Differential binding of Sp1 and Sp3 to this promoter segment is noticeable in the case of the mutant oligonucleotide B. The formation of Sp1 complexes (complex II) is enhanced in the presence of B (lanes 3, 9), but Sp3 binds poorly if at all to this mutant (lanes 3, 9) .
The different behavior of B and A not only confirms the specificity of complex formation, but it also establishes the fact that binding element B is the most critical element for the interaction of Sp1. On the other hand, elimination of site A in mutant B decreases complex formation by Sp3 but has less effect on formation of complexes with Sp1 (lanes 3, 9) . This finding suggests that site B may be most critical for the binding of both Sp1 and Sp3 and that Sp1 readily competes with Sp3 for access to this site. Identical findings were made with CHRF-288-11 or K562 nuclear extracts (not shown).
In a separate gel mobility shift assay (Figure 4) , we tested the ability of the consensus Sp1-binding oligonucleotide 5Ј-ATTC-GATCGGGGCGGGGCGAGC-3Ј (Sp1*) (Promega) to inhibit complex formation with Ϫ52C or Ϫ52T. To facilitate comparisons of protein complexes, lane 1 from Figure 3 (Table 2) either in the absence of antiserum (lanes 1-4) or following incubation with anti-Sp1 (lanes 5, 6, 14, 15), anti-Sp3 (lanes 7-9), anti-AP2 (lanes 10, 11), or anti-NFB (lanes 12, 13). The radiolabeled nucleotide probes (Table 2) 
Reporter assays
To investigate how decreased affinity of the Ϫ52T sequence might influence in situ transcription rates, we compared the relative activities of promoter-LUC constructs. The construct p␣ 2 240-LUC contains the consensus promoter sequence from Ϫ244 through ϩ40 (GenBank accession no. AF062039) with Ϫ52C. This sequence, derived from a comparison of 62 haplotypes, is not identical to the published ␣ 2 promoter sequence 18 but can be considered the allele sequence most equivalent to that published sequence. The plasmid construct p␣ 2 240⌬Ϫ52T-LUC contains the replacement T at Ϫ52. Each construct was ligated into the vector pGL2-enhancer (Promega). Promoter activities were compared after transient transfection of Dami cells or CHRF-288-11 cells. Cotransfection with the vector pSV-␤-galactosidase (Promega) was employed to normalize for transfection efficiency. The results of these assays are summarized in Table 3 .
Dramatic differences were observed in both Dami cells and CHRF-288-11 cells. In Dami cells (3 separate experiments), ⌬Ϫ52T results in a 5-fold decrease in promoter activity. This finding is consistent with a decrease in the binding of Sp1 to the oligonucleotide region encompassing the Ϫ52T substitution. In the Dami cell transfectants, this translates into a decrease in reporter gene activity. As for CHRF-288-11, comparable results were obtained. In 2 experiments, Ϫ52T caused an 8-fold decrease in promoter activity (Table 3 ). In the case of either cell line, individual nonparametric tests of C versus T were statistically significant at the .05 level using the Wilcoxon test.
Discussion
The down-regulation in the expression of integrin ␣ 2 ␤ 1 on platelets has now been well documented by a number of laboratories. [4] [5] [6] [7] However, until this report, a molecular basis for this effect had not been identified. In this study, we provide the first evidence that a naturally occurring single nucleotide substitution, Ϫ52CϾT , lying precisely between 2 tandem Sp1/Sp3 binding elements of the proximal promoter region of the ␣ 2 gene, accounts for a substantial portion of the differences seen in expression of this integrin on platelets. Our evidence for this conclusion is 3-fold. First, in transient transfection assays, promoter-LUC reporter gene constructs that contain the CϾT substitution at nucleotide Ϫ52 exhibit 5-fold to 10-fold decreases in activity in Dami or CHRF-288-11 cells, respectively. Second, in gel mobility shift assays, the CϾT substitution at nucleotide Ϫ52 causes a striking inhibition in the binding of Sp1 and Sp3 present in nuclear extracts of Dami or CHRF-288-11 cells. Third, in a population of 67 healthy donors, the expression of Ϫ52T correlates with decreased expression of the integrin ␣ 2 ␤ 1 on platelets, acting synergistically with previously defined ␣ 2 allelic differences.
The involvement of Sp1 and Sp3 in the regulation of ␣ 2 gene transcription by Ϫ52CϾT is not surprising, based on previous studies of the ␣ 2 gene 5Ј regulatory region. The core promoter of the ␣ 2 gene does not contain a TATA box, but 5 potential Sp1/Sp3 sites are found within the first 311 bp of the 5Ј flanking region. 14, 15 Two of these, tandem Sp1/Sp3 sites within Ϫ30 to Ϫ65, are absolutely necessary for high-level promoter activity in hematopoietic cell lines, such as K562, 14 and represent an Erb-B2 responsive element in human epithelial cells. 15 Acting in cooperation with other regulatory proteins and transcriptional activators, small changes in the activity of Sp1 can cause significant changes in the rate of transcription. For example, Sp1 plays a pivotal role in the cytokine-regulated expression of the vascular cell adhesion molecule and in AP2-regulated, myeloid cell-specific expression of the CDC11c gene. 27, 28 On the other hand, by binding competitively to the same Sp1 consensus elements, Sp3 can either suppress Sp1-mediated transcriptional activation 15, 29, 30 or stimulate transcription in its own right. 31 Thus, the degree to which ␣ 2 Sp1-binding elements are involved in transcription may be influenced by the relative binding of Sp1 (as activator) or Sp3 (as repressor). In this regard, a pertinent feature of the ␣ 2 Sp1 sites is their relatively high affinity for Sp3, as described previously by Ye et al 15 and confirmed by our observations in this report.
In this study, based on comparisons of mutated promoter constructs in mobility shift assays, it appears that the 5Ј site (site B) is more critical to both Sp1 and Sp3 binding than the 3Ј site (site A) in the context of Ϫ52C. When site B alone is eliminated, the binding of both Sp1 and Sp3 is virtually abolished. The elimination of the 3Ј site (site A), however, decreases the binding of Sp3 but markedly enhances the binding of Sp1. The following explanation is consistent with these findings. First, site A alone is not an efficient binding site for either Sp1 or Sp3. Second, Sp1 and Sp3 can compete for binding site B, but the avidity or affinity of Sp1 for this site exceeds that of Sp3. Third, the presence of site A actually inhibits the binding of both Sp1 and Sp3 to site B, possibly through a secondary structure that is peculiar to this segment of the DNA molecule. Thus, the elimination of site A releases the inhibition of Sp1/Sp3 binding to site B. These relationships hold true in the presence of Ϫ52T. However, the binding of Sp1 or Sp3 to site B is markedly decreased in the presence of Ϫ52T, so that any binding differences that might be caused by site A are attenuated. Ye et al 15 did not note any differential binding of Sp1 or Sp3 to sites A or B because they treated these sites as a single binding unit. A precise understanding of the relative contribution of each site to Sp1-and Sp3-regulated promoter activity in situ will require more rigorous molecular analyses and is beyond the scope of this initial report.
The degree of segregation between Ϫ52CϾT and each of the other allelic dimorphisms within the human ␣ 2 genes will require additional studies on a larger number of individuals. However, we have obtained sufficient data to conclude that Ϫ52T is in linkage disequilibrium with the previously defined allele A3, characterized by the allelic sequences 807C and 1648A (HPA-5b). 24, 25 Allele A3 is the least common of the 3 major alleles (gene frequency of 0.08) and has been associated with decreased expression of the integrin on platelets. From an evolutionary standpoint, these data indicate that allele A3 is the youngest of the 3 alleles and that the divergence at Ϫ52CϾT occurred prior to the mutational events that created allele A3. Thus, allele A3 was probably created by mutation of an allele that already bore Ϫ52T. Alleles A1 and A2, on the other hand, continued to express either Ϫ52C or Ϫ52T.
The importance of Sp1 in the transcriptional regulation of other For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From human genes is well established. For example, a point mutation in a single Sp1 site within the human retinoblastoma gene leads to hereditary retinoblastoma, 32 and naturally occurring point mutations within the human ␥-globin promoter cause increased Sp1 binding in vitro and are linked to hereditary persistence of fetal hemoglobin. 33, 34 In the case of the human ␣ 2 gene, allelic differences have a profound effect on expression of the platelet integrin ␣ 2 ␤ 1 , and these expression differences can influence morbidity and risk of fatality in certain disease states, where platelet adhesive function is critical. Inheritance of those alleles that are associated with low receptor density, alleles A2 or A3, may predispose patients with type 1 von Willebrand disease to increased risk of bleeding, 8 and inheritance of allele A1, associated with high receptor density, represents a risk factor for diabetic retinopathy 9 and for acute coronary disease (eg, myocardial infarction) or stroke in younger patients. 10, 11 In this report, we identify for the first time a molecular difference between ␣ 2 alleles that contributes to alleledependent transcriptional regulation of this gene. These findings will pave the way for a more thorough characterization of the mechanisms that control expression of this important receptor.
